Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.
Sitryx Therapeutics has raised $39.0M in total funding. The most recent round was Series A. The last funding was announced in September 2023.
Sitryx Therapeutics's investors include Eli Lilly, Sofinnova Partners, Oxford Science Enterprises, SV Health Investors, Longwood Fund.
Sitryx Therapeutics is headquartered in Oxford, United Kingdom.
Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.
Sitryx Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sitryx Therapeutics — Funding & Investors." VCBacked, September 27, 2023, https://www.vcbacked.co/company/sitryx-therapeutics. Accessed October 26, 2026.
VCBacked. (2023). Sitryx Therapeutics — Funding & Investors. Retrieved October 26, 2026, from https://www.vcbacked.co/company/sitryx-therapeutics
{{cite web |title=Sitryx Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sitryx-therapeutics |website=VCBacked |access-date=October 26, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated